Mesoporous silica nanoparticles in medicine-Recent advances

Veronika Mamaeva, Cecilia Sahlgren*, Mika Lindén

*Corresponding author for this work

Research output: Contribution to journalReview Article or Literature Reviewpeer-review

524 Citations (Scopus)


MSNs have attracted increasing interest as drug carriers due to promising in vivo results in small-animal disease models, especially related to cancer therapy. In most cases small hydrophobic drugs have been used, but recent in vitro studies demonstrate that MSNs are highly interesting for gene delivery applications. This review covers recent advances related to the therapeutic use of mesoporous silica nanoparticles (MSNs) administered intravenously, intraperitoneally or locally. We also cover the use of MSNs in alternative modes of therapy such as photodynamic therapy and multidrug therapy. We further discuss the current understanding about the biodistribution and safety of MSNs. Finally, we critically discuss burning questions especially related to experimental design of in vivo studies in order to enable a fast transition to clinical trials of this promising drug delivery platform.

Original languageEnglish
Pages (from-to)689-702
Number of pages14
JournalAdvanced Drug Delivery Reviews
Issue number5
Publication statusPublished - May 2013
MoE publication typeA2 Review article in a scientific journal


  • Biodistribution
  • Gene delivery
  • Mesoporous silica
  • MSN
  • Nanotoxicology
  • Targeted drug delivery


Dive into the research topics of 'Mesoporous silica nanoparticles in medicine-Recent advances'. Together they form a unique fingerprint.

Cite this